19. Use of fulvestrant in the preparation of a pharmaceutical formulation
for the treatment of a benign or malignant disease of the breast or reproductive tract by intra-muscular administration, wherein the pharmaceutical formulation comprises fulvestrant, 17-23% weight of a
pharmaceutically-acceptable alcohol per volume of formulation,
12-18% weight of pharmaceutically-acceptable non-aqueous ester
solvent miscible in a ricinoleate vehicle per volume of formulation and

Seite 14
O2015_012